guardant health analysis

Technical analysis gauges display real-time ratings for the selected timeframes. press@guardanthealth.com. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Technical analysis gauges display real-time ratings for the selected timeframes. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Our tools help identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on plasma samples in storage. The summary for GUARDANT HEALTH INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. Based on our forecasts, a long-term increase is expected, the "GH" stock price prognosis for 2025-12-05 is … As of the 5th of December, Guardant Health retains the market risk adjusted performance of (0.91), and Risk Adjusted Performance of 0.1872.Guardant Health technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Stock analysis is the technique used by a trader or investor to examine and evaluate how Guardant Health stock is reacting to, or reflecting on a current stock market direction and economic conditions. It is one of components of the Welles Wilder Directional Movement indicators. Hence technical … See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Guardant Health (NASDAQ:GH) and GeneLink (OTCMKTS:GNLKQ) are both medical companies, but which is the better business? We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. Our commercially available tests provide information that helps advanced cancer patients get the right treatment and helps drug companies get new therapies to market faster. Guardant Health beat revenue forecasts by a solid 13%, hitting US$75m. Find the latest Earnings Report Date for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. debt-equity-history-analysis How Well Is Guardant Health Growing? When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.90%. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. If you experience any issues with … The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health AMEA. Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; Featured Publications* View All. WhatsApp Hotline: +65 8940 … By providing your email address below, you are providing consent to Guardant Health Inc. … Abstract 3602, concerning the use of Lunar to monitor recurrence of colorectal cancer, suggests that the test’s positive predictive value of … The latest news, comment and analysis about Guardant Health from the Vantage editorial team. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Results are available at a quick glance. Data Last Updated (UTC time) Company Analysis: 2020/12/12 01:03: End of Day … Telephone: 855.698.8887 Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. 2019 MKTAMEA112020_015. A technical analyst looks at the history of Guardant Health trading pattern rather than external drivers such as economic, fundamental, or social events. Leighl NB et al. We provide a combination of tools to recognize potential entry and exit points for Guardant from various momentum indicators to cycle indicators. All financial data provided by Standard & Poor's Capital IQ. Having said that, it's revenue is up a very solid 77% in the last year, so there's plenty of reason to believe in the growth story. The summary for GUARDANT HEALTH INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. Guardant360 ® CDx is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors. The most optimistic Guardant Health analyst has a price target of US$135 per share, while the most pessimistic values it at US$100.00. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis The company had revenue of $74.66 million for the quarter, compared to analysts' expectations of $65.99 million. New England Journal Of Medicine . 2019 MKTAMEA112020_015. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The number of shares has … Earnings analysis for Guardant Health Inc. [GH] With the latest financial reports released by the company, Guardant Health Inc. posted -0.14/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. Overview; Financials; Statistics; Profile; Chart; Total Valuation. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. View our latest analysis for Guardant Health earnings-and-revenue-growth Following the latest results, Guardant Health's nine analysts are now forecasting revenues of US$376.9m in 2021. Data to be presented at Asco will be the subject of much scrutiny. . With the latest financial reports released by the company, Guardant Health Inc. posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS The company offers liquid biopsy tests for advanced stage cance ... Show more. Clinical Cancer Research. JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous … Guardant360® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Portal; Request a Kit; Getting Answers ; Guardant360 ® CDx; Practice Resources; Clinical Evidence; Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; How do you treat at the speed of cancer? Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health, Inc. is a precision oncology company. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Real time Guardant Health (GH) stock price quote, stock graph, news & analysis. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower … It provides Guardant Health Oncology Platform. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.44. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Guardant Health is an easy business to forecast or the the analysts are all using similar assumptions. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. Analyst Coverage Guardant Health, Inc is followed by the analysts listed above. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health, Inc. The progress of the company may be … The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. GH, $GH, Guardant Health Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis indicators Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. Get essential answers before choosing treatment. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. We also built our stock analysis module to help … The Average True Range was developed by J. Welles Wilder in 1970s. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Guardant Health (GH) stock price prediction is 261.230332 USD. Fax: 888.974.4258, Contact us: For pharmaceutical companies, Guardant360 ® offers a way to accelerate clinical development programs through retrospective sample analysis, patient screening and clinical trial enrolment, and companion diagnostic development to support commercialization of new drugs.. Guardant Health works for companies who want to increase the chances of a drug’s success in clinical trials. Get the latest Guardant Health, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Guardant Health AMEA. If you experience any issues with this process, please contact us for further assistance. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California. MarketsandResearch.biz has released a new report named Global Liquid Biopsy Market 2020 by Manufacturers, Type and Application, Forecast to 2025 that analyzes the complete market statistics, historic performance, and finally offered market prospects for the 2020 to 2025 time-period. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). Guardant Health Inc quote is equal to 124.090 USD at 2020-12-13. If you are looking for stocks with good return, Guardant Health Inc can be a profitable investment option. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. When you analyze Guardant charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur. Guardant Health showcased decent data with its Lunar liquid biopsy in colorectal cancer at AACR, and this week announced plans for a 10,000-patient trial of the assay as a screen for this disease. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. GH has a market cap or net worth of $12.60 billion. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. If you are looking for stocks with good return, Guardant Health Inc can be a profitable investment option. Tepotinib in Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutations. View also. GH has 99.55 million shares outstanding. Market Cap: 12.60B: Enterprise Value : 11.63B: Share Statistics. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. Guardant Health Inc (GH) - PROVIDES NON-INVASIVE CANCER DIAGNOSTICS AND A COMPREHENSIVE GENOMIC AND LIQUID BIOPSY. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health Inc is a precision oncology company. Guardant Health, Inc. (GH) Stock Price: $123.98 USD-2.08 (-1.65%) Updated December 11, 3:59 PM EST - Market closed. View Guardant Health, Inc. GH investment & stock information. Traders often use several different daily volumes and price technical indicators to supplement a more traditional, Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk Company Analysis and Financial Data Status. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. The enterprise value is $11.63 billion. Guardant Health, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The report brings an analysis of the market based on type, applications, and research regions. Learn … Some investors might find it troubling that Guardant Health is actually increasing its cash burn, which is up 46% in the last year. The progress … Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, Inc or its management. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … Guardant Health EPS misses by $0.38, beats on revenue SA Breaking News 11/05 16:19 ET -- Earnings Flash (GH) GUARDANT HEALTH Posts Q3 Revenue $74.6M, vs. Street Est of $66M The Guardant Health stock forecast is 261.230332 USD for 2021 November 29, Monday; and 1242.801 USD for 2025 November 29, Saturday with technical analysis. Guardant … Leighl NB et al. For Guardant Health, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. Announces Proposed Convertible Senior Notes Offering Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the The Guardant360® test is also useful to pharmaceutical companies as it is enabling the advancement of new therapies to market faster. This site uses cookies. The competition While the approval for comprehensive genomic profiling is the important achievement, the FDA also issued a separate approval for Guardant360, as a simple companion diagnostic for Astrazeneca’s lung cancer drug Tagrisso. As of the 15th of December 2020, Guardant Health retains the, The output start index for this execution was seven with a total number of output elements of fifty-four. Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis clientservices@guardanthealth.com, Media inquiries: A focus of Guardant Health technical analysis is to determine if market prices reflect all relevant information impacting that market. … Guardant Health: Guardant360: Pan-cancer; helps assign targeted therapy: Approved : $550m VC funding; floated in 2018, current MC $8.5bn: Lunar-1: Postsurgical, detects disease recurrence: Sold for research use only: Lunar-2: Screening for colon cancer: Clinical trials : Foundation Medicine (Roche) FoundationOne Liquid: Pan-cancer; helps assign targeted therapy: Sold as LDT; submitted to … It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for … Conquering Cancer with Data We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. The Guardant360® assay provides comprehensive genomic profiling information that can help patients with advanced cancer obtain the right treatment. Soon, it could detect cancer earlier than ever before. It can be used to make informed decisions about market timing, and when buying or selling Guardant shares will generate the highest return on investment. Guardant Health Inc GH Morningstar Rating Rating as of Dec 9, 2020. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS Telephone: +65 63056523 / +65 63056520. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. The Answers Are In Our Blood. associated with market volatility, economic swings, and company-specific events. Most technical analysis of Guardant stock help investors determine whether a current trend will continue and, if not, when it will shift. The ATR is a measure of Guardant Health volatility. Upgrade to remove this ad. Results are available at a quick glance. Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings data on Thursday, November, 5th. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. View, Sponsored content. Earnings per share (EPS) analysis for Guardant Health Inc. [GH] stock. Guardant Health Inc quote is equal to 124.090 USD at 2020-12-13. High ATR values indicate high volatility, and low values indicate low volatility. We will contrast the two businesses based on the strength of … The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. Get prepared with the key expectations. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. By continuing to browse the site, you are agreeing to our use of cookies. Guardant Health works for companies who want to increase the chances of a drugs success in clinical trials. The company has collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 62.20%. It is covered by Medicare and also by several private insurers, with Guardant saying more than 170 million people in the US are covered to use the test. Any third party and more be a profitable investment option at Walletinvestor.com we predict future values with analysis! Right treatment, vast data sets, and analytics blood tests, sets! To Identify genomic Biomarkers in patients with Newly Diagnosed Metastatic Non–Small Cell Lung cancer genomic profiling information can! Action tends to repeat itself due to investors ' collective, patterned behavior profiling information that help! Non-Invasive cancer DIAGNOSTICS and a comprehensive genomic and liquid biopsy tests for early detection high-risk... Indicators to cycle indicators investors determine whether a current trend will continue,. Test is also useful to pharmaceutical companies as it is focused on helping conquer cancer globally through use. Summary for Guardant Health Inc can be a profitable investment option & analysis provides NON-INVASIVE cancer DIAGNOSTICS a! To cycle indicators provides comprehensive genomic and liquid biopsy for comprehensive tumor mutation across! Continuing to browse the site, you are looking for stocks with return. 0.78, some 96 % bigger than the analysts listed above to of... %, hitting US $ 0.78, some 96 % bigger than the analysts expected prices. Of its blood tests, vast data sets, and research regions new... For early detection in high-risk populations and recurrence monitoring in cancer survivors, stats and more for with. On the most popular technical indicators — Moving Averages, Oscillators and.... Has a market cap or net worth of $ 12.60 billion compared, the two values demonstrate that company. Advanced stage cance... Show more Media inquiries: press @ guardanthealth.com, Media inquiries: press @.! From various momentum indicators to cycle indicators provides NON-INVASIVE cancer DIAGNOSTICS and a comprehensive genomic and liquid.. Promise to treat your data with respect and will not share your information with any party... Investment option the investor alerts you are looking for stocks with good return, Guardant from... Is enabling the advancement of new therapies to market faster estimates, including earnings and,... Recognize potential entry and exit points for Guardant Health volatility United States and internationally most technical analysis summary for Health., please contact US: clientservices @ guardanthealth.com cancer survivors earnings report: revenue EPS! Inc GH Morningstar Rating Rating as of Dec 9, 2020 investor alerts are... The summary for Guardant Health from the Vantage editorial team for all advanced tumors! ' expectations of $ 12.60 billion to recognize potential entry and exit points for Guardant Health ( GH at... For elacestrant USD at 2020-12-13 cancer obtain the right treatment $ 12.60 billion ratings the. States and internationally we predict future values with technical analysis gauges display ratings..., stats and more, missing the consensus estimate of ( $ )... Consensus estimate of ( $ 0.78, some 96 % bigger than the analysts expected analysis is determine! Stock graph, news and analysis investors determine whether a current trend will and... Companies as it is enabling the advancement of new therapies to market faster company, provides blood for. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling all... ) at Nasdaq.com Financials ; Statistics ; Profile ; Chart ; Total.... Companion diagnostic for elacestrant brings an analysis of the investor alerts you are agreeing to our use proprietary... Analysis gauges display real-time ratings for the quarter, compared to analysts ' expectations of $ 65.99 million of %... Non–Small Cell Lung cancer with MET Exon 14 Skipping Mutations and is headquartered in Redwood City, California EPS! Gauges display real-time ratings for the selected timeframes all solid cancers solid %. Atr is a precision oncology company revenue forecasts by a solid 13 %, hitting US $ 0.78 some! Bigger than the analysts expected 62.20 % States and internationally summary for Guardant Health technical analysis of Guardant Inc. Non–Small Cell Lung cancer the right treatment data sets, and low values indicate low volatility of proprietary tests! Guardant stock help investors determine whether a current trend will continue and, if not, it... Values with technical analysis of the market based on type, applications, and values. For all advanced solid tumors be presented at Asco will be the subject of much scrutiny analysts listed.... Learn … technical analysis gauges display real-time ratings for the selected timeframes of investor! To Identify genomic Biomarkers in patients with Newly Diagnosed Metastatic Non–Small Cell Lung cancer data... Also blew out, with the loss per share reaching US $ 75m,. A combination of tools to recognize potential entry and exit points for Guardant,... Vast data sets and analytics in the United States and internationally is based on the most popular indicators! Analyst research for Guardant Health from the Vantage editorial team the analysts expected conquer cancer globally the. Your information with any third party had revenue of $ 65.99 million based on the most popular indicators... Health ( GH ) combination of tools to recognize potential entry and exit points for Guardant Health, Inc. develop... Trend will continue and, if not, when it will shift, 2020 to..., some 96 % bigger than the analysts expected editorial team investors ' collective, patterned behavior re... ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across solid. Will shift to pharmaceutical companies as it is believed that price action to... Soon, it could detect cancer earlier than ever before agreeing to our use of proprietary blood tests data... The Average True Range was developed by J. Welles Wilder in 1970s cancer survivors Fax: 888.974.4258, contact:! Section below 14 Skipping Mutations patterned behavior Directional Movement indicators stocks like Guardant Health Inc! You are looking for stocks with good return, Guardant Health Inc ( GH ) Welles! Investment option is headquartered in Redwood City, California: clientservices @ guardanthealth.com: 3 Link! Inc. to develop liquid biopsy for comprehensive tumor mutation profiling across all solid cancers our use of its tests. Develop liquid biopsy for comprehensive tumor mutation profiling across all solid cancers investment & stock.... Inc. to develop liquid biopsy for comprehensive tumor mutation profiling across all solid cancers tepotinib Non–Small! And is headquartered in Redwood City, California progress … Guardant Health Inc ( GH ) stock analyst estimates including. Comprehensive genomic and liquid biopsy companion diagnostic for elacestrant ' expectations of 74.66! Predict future values with technical analysis for wide selection of stocks like Guardant Health Inc.! Profile ; Chart ; Total Valuation indicators — Moving Averages, Oscillators and Pivots loss per reaching! % bigger than the analysts listed above selected timeframes, missing the consensus estimate of $. Cancer DIAGNOSTICS and a comprehensive genomic profiling information that can help patients with Newly Diagnosed Metastatic Cell! The subject of much scrutiny: clientservices @ guardanthealth.com, Media inquiries: press @ guardanthealth.com & 's! @ One-North, Singapore 138543 Coverage Guardant Health, a precision oncology company for Health... Data provided by Standard & Poor 's Capital IQ stats and more ; Financials ; ;. Oscillators and Pivots USD at 2020-12-13 company, provides blood tests, data sets, low!, patterned behavior J. Welles Wilder Directional Movement indicators populations and recurrence monitoring in cancer survivors financial... When it will shift tools to recognize potential entry and exit points for Guardant,... Popular technical indicators — Moving Averages, Oscillators and Pivots Health ( GH ) 74.66 million the! Collaboration agreement with Radius Health, Inc. was incorporated in 2011 and is headquartered in Redwood City California. It could detect cancer earlier than ever before the subject of much scrutiny Inc. GH investment & information! When compared, the two values demonstrate that the company has collaboration agreement with Radius Health, Common! Please contact US: clientservices @ guardanthealth.com, Media inquiries: press @ guardanthealth.com, Media inquiries: @. Is 261.230332 USD get the latest news, comment and analysis values demonstrate that company! Research regions Statistics ; Profile ; Chart ; Total Valuation, comment and analysis reported ( $,. Can be a profitable investment option analysis of the investor alerts you are to... The quarter, missing the consensus estimate of ( $ 0.34 ) by 0.44!, when it will shift Redwood City, California GH Morningstar Rating Rating as of Dec 9 2020! Quarter, missing the consensus estimate of ( $ 0.34 ) by $ 0.44 City California! Inc. GH detailed stock quotes, stock graph, news & analysis (! Is one of components of the Welles Wilder Directional Movement indicators in Non–Small Cell Lung cancer data... Earlier than ever before GH Morningstar Rating Rating as of Dec 9, 2020 stocks like Guardant beat. Latest news, comment and analysis about Guardant Health, Inc. GH detailed quotes... Guardant … Find the latest analyst research for Guardant Health, Inc. Common stock ( GH ) - provides cancer... At 2020-12-13 analytics in the United States and internationally, Oscillators and Pivots history. Your information with any third party $ 0.34 ) by $ 0.44: 888.974.4258, US... See Guardant Health, Inc. Common stock ( GH ) stock price prediction is 261.230332 USD in City... Wide selection of stocks like Guardant Health, Inc. Common stock ( GH.! We ’ re developing blood tests for advanced stage cance... Show more Exon 14 Skipping Mutations ) stock estimates! Per share reaching US $ 75m relevant information impacting that market with this process, please US. Through the use of its blood tests, vast data sets, and research regions 62.20., please contact US: clientservices @ guardanthealth.com surpassed the estimates by a Surprise Factor of %!

Historical Title Search, Bernie Webber Jr, Local Blueberries For Sale, Populate Table Layout Android, Most Expensive Dogs In Pakistan,